SCHEMBL4394192

SCHEMBL4394192

COC(=O)c1ccc(-c2ccc(C=C3SC(=S)N(CCc4ccc(OC)c(OC)c4)C3=O)o2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
POLB P06746 3/20 0.62
ALDH1A1 P00352 2/20 0.62
MAPT P10636 2/20 0.62
USP2 O75604 1/20 0.62
MAPK1 P28482 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
STAT3 P40763 1/20 0.56
MAP3K5 Q99683 4/20 0.56
PTPN22 Q9Y2R2 3/20 0.55
EP300 Q09472 1/20 0.53
CREBBP Q92793 1/20 0.53
HSPD1 P10809 1/20 0.53
HSPE1 P61604 1/20 0.53
HIF1AN Q9NWT6 1/20 0.52
PKM P14618 2/20 0.52
PTPN7 P35236 2/20 0.52
PTPN12 Q05209 2/20 0.52
MCL1 Q07820 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4394189 1.00 MEN1 (0.62) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL13592708 1.00 MEN1 (0.62) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL4394171 0.93 STAT3 (0.66) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL4394822 0.88 EP300 (0.69) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL14025845 0.88 EP300 (0.69) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL4394820 0.88 EP300 (0.69) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL14025843 0.86 EP300 (0.73) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL14045885 0.86 MEN1 (0.63) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL4396750 0.86 EP300 (0.73) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL4396439 0.86 EP300 (0.73) MEN1KMT2APOLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP claimed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US claimed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP claimed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO claimed
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP disclosed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP disclosed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN MEN1 2216/4885KMT2A 1040/4885POLB 1570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.